Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoThelium FT
- Development stage
- Preclinical
- Lead developer
- NuScience Medical Biologics
- Modality
- Cell Therapies
- Administration
- Topical
01
Overview
NeoThelium FT is a dehydrated, dual-layer human placental tissue graft consisting of amnion and chorion layers. Developed by NuScience Medical Biologics, it is processed as a Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) under Section 361 of the Public Health Service Act. The graft serves as a biological scaffold and wound covering, providing a natural extracellular matrix, growth factors, and cytokines to promote healing in chronic wounds. It is primarily investigated for the management of diabetic foot ulcers, venous leg ulcers, and pressure injuries.
- Brand names
- NeoThelium FT
- Other names
- NeoThelium FT Amnion Skin Graft
Beyond the preview
Go deeper on NeoThelium FT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoThelium FT.